Drug Profile
ASP 3325
Alternative Names: ASP3325Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class Hyperphosphataemia therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hyperphosphataemia
Most Recent Events
- 31 May 2015 Discontinued - Phase-I for Hyperphosphataemia in Japan (PO)
- 01 Aug 2013 Phase-I clinical trials in Hyperphosphataemia in Japan (PO) (NCT02500953)